Around ten years ago, the first evidence that targeting microtubule system could be a potential strategy
in slowing down neurodegeneration was reported. Several teams have been working to better shape this idea and
the scientific community has now the opportunity of fishing into a large amount of data coming from in vitro and
in in vivo studies. Notably, these results have driven clinical trials addressing tauopathies. Unfortunately, moving
such a neuroprotective strategy from mice to men has revealed unexpected concerns and results that do not fit
with the promising background. Here we aim to focus the rationale for the design of a microtubule-based therapy
in neurodegeneration, look at the results achieved and discuss the future perspectives.